CSL boosts half-year profit by 7%
CSL (ASX:CSL) grew its post-tax profit for the half-year ending in December by 7% to US$692 million ($890.3 million), on the back of solid revenue growth.
Group revenue increased by 6% year-on-year to US$2.8 billion, with plasma subsidiary CSL Behring lifting its sales by 8% to US$2.5 billion.
Albumin sales grew 16% in constant currency terms to US$358 million, making it the subsidiary’s fastest growing product line. Demand in China was particularly strong during the half year.
The biggest contributor was immunoglobulin product sales, which increased 5% to US$1.12 billion, on the strength of demand in both the US and Europe.
Haemophilia product sales grew 3% in constant currencies to US$558 million, with plasma-derived haemophilia sales up an even stronger 5%. Specialty product sales grew 13% to $443 million, despite a decline in sales of wound-healing products in Japan.
Vaccines division bioCSL meanwhile reported a 15% increase in sales to $276 million, due to strong influenza vaccine sales and the fact that bioCSL took over some commercial operations in the US following the cancellation of a third-party distribution deal.
CSL also earned US$92 million in intellectual property revenue during the six-month period, a 9% year-on-year decline.
CSL (ASX:CSL) shares were trading 7.75% lower at $83.025 as of around 2 pm on Wednesday.
Image credit: ©freeimages.com/profile/miqueias
Shingles vaccine may lower risk of dementia, heart disease
It turns out that the shingles vaccine may have public-health benefits beyond its intended...
How does the brain evaluate rewards?
Neuroscientists have shown how nerve cells in the amygdala not only encode the probability and...
Breakthrough drug prevents long COVID symptoms in mice
Mice treated with the antiviral compound were protected from long-term brain and lung dysfunction...
